Mode
Text Size
Log in / Sign up

Dermatology

121 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Arthroscopy-assisted curettage and bone grafting for proximal femur giant cell tumor in a 25-year-old man
Dermatology
Arthroscopy-assisted curettage and bone grafting for proximal femur giant cell tumor in a 25-year-old man Single case report suggests possible approach for treating a rare bone tumor in the hip
A case report describes a 25-year-old man with a giant cell tumor of the proximal femur who underwent arthroscopy-assisted curettage and bon…
Doctors used a small camera to remove a rare hip tumor in one patient, successfully controlling the growth while keeping the joint working n…
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
Dermatology Guideline
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report Can a psoriasis drug help with a rare, hard-to-treat skin condition?
A case report and literature review describes a 48-year-old male with inverse psoriasis who showed marked improvement in cutaneous lesions a…
A single patient with hard-to-treat inverse psoriasis found marked relief in itching and skin lesions after just three injections of a newer…
PFAS mixture exposure shows positive association with serum total IgE levels in Korean adults
Dermatology
PFAS mixture exposure shows positive association with serum total IgE levels in Korean adults Could everyday chemical exposure be linked to higher allergy markers?
A cross-sectional study of 2,987 Korean adults found a statistically significant positive association between concurrent exposure to a mixtu…
Higher exposure to a mix of five common industrial chemicals was linked to higher allergy markers in nearly 3,000 Korean adults, with one sp…
Nomogram predicts occupational contact dermatitis risk in Chinese nurses with excellent discrimination
Dermatology Cohort
Nomogram predicts occupational contact dermatitis risk in Chinese nurses with excellent discrimination Researchers develop tool to predict skin irritation risk for nurses
An observational cohort study of 2,852 nurses across 40 Chinese hospitals developed and validated a nomogram-based prediction model for occu…
A new tool predicts which nurses face higher skin irritation risk by analyzing nine factors like work habits and sleep duration.
Imiquimod costs substantially less than radiotherapy for lentigo maligna in Australian analysis
Dermatology RCT
Imiquimod costs substantially less than radiotherapy for lentigo maligna in Australian analysis Study finds topical treatment for lentigo maligna costs far less than radiotherapy
A phase 3 RCT-based cost analysis of 118 patients with lentigo maligna found imiquimod had dramatically lower healthcare system (US$72.50 vs…
Topical cream costs just $72 per patient versus over $2,600 for radiotherapy when treating lentigo maligna, a sun-damaged skin condition.
Topical PDE4 inhibitors show efficacy in pediatric atopic dermatitis meta-analysis
Dermatology Meta-analysis
Topical PDE4 inhibitors show efficacy in pediatric atopic dermatitis meta-analysis Could a new cream help kids with eczema find relief faster?
A meta-analysis of 5 RCTs (n=1877) in pediatric mild-to-moderate atopic dermatitis found topical PDE4 inhibitors were associated with higher…
A new class of eczema creams linked to faster relief and better skin clearance in kids, with no increase in side effects compared to standar…
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
Dermatology Phase III
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients Phase 3 trial tests low-dose IL-2 for severe alopecia areata, results pending
A Phase 3, prospective, randomized, double-blind, multicenter trial compared low-dose IL-2 to placebo in 44 patients with severe alopecia ar…
A major late-stage trial testing low-dose IL-2 for severe alopecia areata has finished, but results on hair regrowth are not yet available.
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Dermatology Phase II
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28 Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma
Dermatology Phase II
Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma Can a patient's own immune cells be turned into a treatment for advanced melanoma?
A prospective, multicenter, phase 2 interventional study evaluated lifileucel (autologous tumor-infiltrating lymphocytes, LN-144) infusion a…
A new treatment uses a patient's own immune cells to fight advanced melanoma, but results from the mid-stage trial are not yet available.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Dermatology Phase II
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Dermatology Phase III
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis.
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria
Dermatology Phase III
Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria Can a new treatment finally help those suffering from chronic hives?
A Phase 3 trial assesses barzolvolimab's efficacy and safety in CSU patients unresponsive to antihistamines.
Adults with chronic hives who don't get relief from standard antihistamines may find new hope in a new treatment called barzolvolimab being …